Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice

Abstract

Bacterial infection is a common finding in patients, who develop medication-related osteonecrosis of the jaw (MRONJ) by the long-term and/or high-dose use of anti-resorptive agents such as bisphosphonate (BPs). However, pathological role of bacteria in MRONJ development at the early stage remains controversial. Here, we demonstrated that commensal microbiota protects against MRONJ development in the pulp-exposed periapical periodontitis mouse model. C57/BL6 female mice were treated with intragastric broad-spectrum antibiotics for 1 week. Zoledronic acid (ZOL) through intravenous injection and antibiotics in drinking water were administered for throughout the experiment. Pulp was exposed on the left maxillary first molar, then the mice were left for 5 weeks after which bilateral maxillary first molar was extracted and mice were left for additional 3 weeks to heal. All mice were harvested, and cecum, maxilla, and femurs were collected. ONJ development was assessed using μCT and histologic analyses. When antibiotic was treated in mice, these mice had no weight changes, but developed significantly enlarged ceca compared to the control group (CTL mice). Periapical bone resorption prior to the tooth extraction was similarly prevented when treated with antibiotics, which was confirmed by decreased osteoclasts and inflammation. ZOL treatment with pulp exposure significantly increased bone necrosis as determined by empty lacunae and necrotic bone amount. Furthermore, antibiotics treatment could further exacerbate bone necrosis, with increased osteoclast number. Our findings suggest that the commensal microbiome may play protective role, rather than pathological role, in the early stages of MRONJ development.

References

[1] Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat. Rev. Endocrinol., 2011, 8: 81-91.

[2] Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg., 2005, 63: 1567-1575.

[3] Ruggiero SL, . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral Maxillofac. Surg., 2014, 72: 1938-1956.

[4] Henry DH, . Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol., 2011, 29: 1125-1132.

[5] Martins AS, . Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws—a retrospective cohort study. J. Craniomaxillofac. Surg., 2017, 45: 1736-1742.

[6] Vahtsevanos K, . Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol., 2009, 27: 5356-5362.

[7] Soundia A, . Zoledronate impairs socket healing after extraction of teeth with experimental periodontitis. J. Dent. Res., 2018, 97: 312-320.

[8] Saad F, . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol., 2012, 23: 1341-1347.

[9] Yamazaki T, . Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int. J. Oral Maxillofac. Surg., 2012, 41: 1397-1403.

[10] Aghaloo TL, . Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J. Bone Miner. Res., 2011, 26: 1871-1882.

[11] Ficarra G, . Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J. Clin. Periodontol., 2005, 32: 1123-1128.

[12] Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol., 2008, 44: 857-869.

[13] Kim T, . Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the jaw-like lesion in mice. Am. J. Pathol., 2018, 188: 2318-2327.

[14] Mawardi H, . Sinus tracts-an early sign of bisphosphonate-associated osteonecrosis of the jaws?. J. Oral Maxillofac. Surg., 2009, 67: 593-601.

[15] Kang B, . Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J. Bone Miner. Res., 2013, 28: 1631-1640.

[16] Aguirre JI, . Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J. Bone Miner. Res, 2012, 27: 2130-2143.

[17] Lopez-Jornet P, . Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. J. Oral Maxillofac. Surg., 2011, 69: 2488-2493.

[18] Nair PN. On the causes of persistent apical periodontitis: a review. Int. Endod. J., 2006, 39: 249-281.

[19] Stashenko P, Teles R, D’Souza R. Periapical inflammatory responses and their modulation. Crit. Rev. Oral Biol. Med., 1998, 9: 498-521.

[20] Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J. Dent. Res., 2015, 94: 534-539.

[21] Kos M, . Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw?. J. Oral Maxillofac. Surg., 2013, 71: 1010-1016.

[22] Sedghizadeh PP, . Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J. Am. Dent. Assoc., 2009, 140: 1259-1265.

[23] Ripamonti CI, . Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol., 2009, 20: 137-145.

[24] Sedghizadeh PP, . Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J. Oral Maxillofac. Surg., 2008, 66: 767-775.

[25] Williams DW, . Indigenous microbiota protects against inflammation-induced osteonecrosis. J. Dent. Res., 2020, 99: 676-684.

[26] Song, M. et al. Development of a direct pulp-capping model for the evaluation of pulpal wound healing and reparative dentin formation in mice. J Vis Exp (2017).

[27] Song M, . Preexisting periapical inflammatory condition exacerbates tooth extraction-induced bisphosphonate-related osteonecrosis of the jaw lesions in mice. J. Endod., 2016, 42: 1641-1646.

[28] Gordon HA, Pesti L. The gnotobiotic animal as a tool in the study of host microbial relationships. Bacteriol. Rev., 1971, 35: 390-429.

[29] Dimopoulos MA, . Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol., 2009, 20: 117-120.

[30] Reikvam DH, . Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS ONE, 2011, 6: e17996.

[31] Graves DT, Kang J, Andriankaja O, Wada K, Rossa C Jr. Animal models to study host-bacteria interactions involved in periodontitis. Front. Oral Biol., 2012, 15: 117-132.

[32] Abe T, Hajishengallis G. Optimization of the ligature-induced periodontitis model in mice. J. Immunol. Methods, 2013, 394: 49-54.

[33] Williams DW, . Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am. J. Pathol., 2014, 184: 3084-3093.

[34] Kozutsumi R, . Zoledronic acid deteriorates soft and hard tissue healing of murine tooth extraction sockets in a dose-dependent manner. Calcif. Tissue Int., 2022, 110: 104-116.

[35] Sjogren K, . The gut microbiota regulates bone mass in mice. J. Bone Miner. Res., 2012, 27: 1357-1367.

[36] Kuroshima S, Go VA, Yamashita J. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology, 2012, 153: 17-28.

[37] Lakschevitz FS, . Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp. Cell Res., 2016, 342: 200-209.

[38] Tseng HC, . Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget, 2015, 6: 20002-20025.

[39] Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med., 2009, 360: 53-62.

[40] Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity?. Osteoporos. Int., 2011, 22: 435-446.

[41] Merida S, . Bevacizumab diminishes inflammation in an acute endotoxin-induced Uveitis model. Front. Pharm., 2018, 9: 649.

[42] Kakehashi S, Stanley HR, Fitzgerald RJ. The effects of surgical exposures of dental pulps in germ-free and conventional laboratory rats. Oral Surg. Oral Med. Oral Pathol., 1965, 20: 340-349.

[43] Matsumoto T, . Factors affecting successful prognosis of root canal treatment. J. Endod., 1987, 13: 239-242.

[44] Mawardi H, . A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J. Dent. Res., 2011, 90: 1339-1345.

[45] Bouxsein ML, . Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res., 2010, 25: 1468-1486.

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)(DE023348, DE025172)

China Postdoctoral Science Foundation(2019M663526)

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)